Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT ID: NCT02808104

Last Updated: 2017-04-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 84 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-08-31
• Study Completion Date: 2017-03-28

Brief Summary

The purpose of this study is to determine whether a controlled release formulation of mazindol is more effective than a placebo in the treatment of Attention Hyperactivity Disorder (ADHD) in adults.

Detailed Description

This study is an outpatient, randomized, double-blind, placebo-controlled trial in which adult subjects with ADHD will be randomized to either oral mazindol controlled release or placebo once daily. Subjects will be treated with study medication or placebo for 6 weeks with visits occurring weekly to measure efficacy and any adverse events with adjustment of medication dosing as necessary.

Conditions

Attention Deficit Disorder With Hyperactivity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Mazindol Controlled Release

Mazindol controlled release taken once daily. Dosage starting at 1 mg increasing or decreasing in increments of 1 mg depending on efficacy and tolerability. Maximum dose during the study is 3 mg taken once daily.

Group Type: EXPERIMENTAL

mazindol

Intervention Type: DRUG

Placebo

Matching placebo

Group Type: PLACEBO_COMPARATOR

mazindol

Intervention Type: DRUG

Interventions

mazindol

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subject has a primary diagnosis of ADHD established by a comprehensive psychiatric evaluation based on DSM-5 criteria.
• Subject is functioning at an appropriate level intellectually as judged by the investigator.
• Subject has a minimum baseline score of 28 at screen and at baseline using the ADHD-RS-DSM5
• Subject has a minimum score of 4 (moderate) on the CGI-S at screening.
• Women of child-bearing potential must be non-pregnant, non-lactating, and agree to be on an acceptable method of contraception. Acceptable methods of contraception include intrauterine devices (IUDs), hormonal contraceptives (oral, depot, patch or injectable), and double barrier methods such as condoms or diaphragms with spermicidal gel or foam.
• In good general physical health as determined by medical history, a baseline physical examination, vital signs, clinical laboratory tests and electrocardiogram (ECG) measurement.
• Subject is fluent in written and spoken English and is willing and able to sign written informed consent prior to receipt of any study medication or beginning study procedures.
• Subject is willing and able to follow instructions, comply with the protocol requirements and make all required study visits.

Exclusion Criteria

• Any primary DSM-5 Axis I disorder other than ADHD or any comorbid DSM-5 disorder that currently requires treatment.
• Lifetime history of any DSM-5 bipolar disorder
• Treatment with medications for any psychiatric or neurologic condition (e.g., amphetamines, MPH products, antidepressants, antipsychotics, mood stabilizers, anti-epileptics) or pressor agents concurrently or within 14 days of randomization.
• Concurrent medical illness that would interfere with the conduct of the study in the opinion of the investigator.
• History of significant cardiovascular disease, structural cardiac abnormality, cardiomyopathy, heart failure, serious heart rhythm abnormalities, coronary heart disease, transient ischemic attack or stroke, or other serious cardiac problems.
• Family history of sudden cardiac death.
• Clinically significant ECG abnormality or a QTc (Bazett correction) interval >450 msec.
• Resting sitting systolic blood pressure > 150 mm Hg or diastolic blood pressure > 90 mm Hg.
• BMI <18 or >40 kg/m2.
• Other medications that have CNS effects on cognition or attention (e.g., sedating antihistamines or decongestants).
• Positive drug screen (UDS) at screening (with the exception of current ADHD medication).
• Concomitant use of sensitive CYPA4/5 or CYP2D6 substrates with narrow therapeutic indices.
• Pregnant or lactating.
• Ongoing psychotherapeutic treatment for the treatment of ADHD begun less than three months before entry into this study.
• Recent or current DSM-5 Substance Use Disorder of moderate or greater severity (i.e., > 4 SUD symptoms), excluding nicotine.
• Suicidal ideation within past 3 months, suicidal behavior within the past year, or a C-SSRS score of 3, 4 or 5 on ideation item.
• Evidence of any out-of-range laboratory value at screening that has not been reviewed, approved and documented as not clinically significant by the Study Investigator.
• A history of significant drug allergy or systemic allergic disease (e.g., urticaria, atopic dermatitis), or any known/suspected hypersensitivity to any form of mazindol.
• Any other condition or clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening that, in the opinion of the Study Investigator, would make the subject unsuitable for the study or put them at additional risk.
• Treatment with an investigational drug within 30 days preceding the first dose of study medication.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

NLS Pharmaceutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

AVIDA Clinic

Newport Beach, California, United States

CNS Healthcare

Jacksonville, Florida, United States

South Shore Psychiatric Services

Marshfield, Massachusetts, United States

Rochester Center for Behavorial Medicine

Rochester Hills, Michigan, United States

Midwest Research Group / St. Charles Psychiatric Associates

Saint Charles, Missouri, United States

Clinical Neuroscience Solutions

Memphis, Tennessee, United States

Memorial Park Psychiatry / Bayou City Research

Houston, Texas, United States

Countries

United States

References

Wigal TL, Newcorn JH, Handal N, Wigal SB, Mulligan I, Schmith V, Konofal E. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). CNS Drugs. 2018 Mar;32(3):289-301. doi: 10.1007/s40263-018-0503-y.

Reference Type: DERIVED

PMID: 29557078 (View on PubMed)

Other Identifiers

NLS-1001

Identifier Type: -

Identifier Source: org_study_id